CoChat

Assessing the landscape of STXBP1 -related disorders in 534 individuals

Open access

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Abstract

Disease-causing variants in STXBP1 are among the most common genetic causes of neurodevelopmental disorders. However, the phenotypic spectrum in STXBP1-related disorders is wide and clear correlations between variant type and clinical features have not been observed so far. Here, we harmonized clinical data across 534 individuals with STXBP1-related disorders and analysed 19 973 derived phenotypic terms, including phenotypes of 253 individuals previously unreported in the scientific literature. The overall phenotypic landscape in STXBP1-related disorders is characterized by neurodevelopmental abnormalities in 95% and seizures in 89% of individuals, including focal-onset seizures as the most common seizure type (47%). More than 88% of individuals with STXBP1-related disorders have seizure onset in the first year of life, including neonatal seizure onset in 47%. Individuals with protein-truncating variants and deletions in STXBP1 (n = 261) were almost twice as likely to present with West syndrome and were more phenotypically similar than expected by chance. Five genetic hotspots with recurrent variants were identified in more than 10 individuals, including p.Arg406Cys/His (n = 40), p.Arg292Cys/His/Leu/Pro (n = 30), p.Arg551Cys/Gly/His/Leu (n = 24), p.Pro139Leu (n = 12), and p.Arg190Trp (n = 11). None of the recurrent variants were significantly associated with distinct electroclinical syndromes, single phenotypic features, or showed overall clinical similarity, indicating that the baseline variability in STXBP1-related disorders is too high for discrete phenotypic subgroups to emerge. We then reconstructed the seizure history in 62 individuals with STXBP1-related disorders in detail, retrospectively assigning seizure type and seizure frequency monthly across 4433 time intervals, and retrieved 251 anti-seizure medication prescriptions from the electronic medical records. We demonstrate a dynamic pattern of seizure control and complex interplay with response to specific medications particularly in the first year of life when seizures in STXBP1-related disorders are the most prominent. Adrenocorticotropic hormone and phenobarbital were more likely to initially reduce seizure frequency in infantile spasms and focal seizures compared to other treatment options, while the ketogenic diet was most effective in maintaining seizure freedom. In summary, we demonstrate how the multidimensional spectrum of phenotypic features in STXBP1-related disorders can be assessed using a computational phenotype framework to facilitate the development of future precision-medicine approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awab327

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of STXBP1 variants. (A) Recurrent STXBP1 variants found in five or more individuals. (B) The STXBP1 protein (top) and gene (bottom), highlighting a selection of recurrent variant hotspots. The proportion of STXBP1 disorder-associated versus population variants is shown below, highlighting (grey) regions in which the difference is significant. (C) Distribution of variant types. Splice site, frameshift variants and whole and partial gene deletions were included in the PTV/del group.
Figure 1 Overview of STXBP1 variants. (A) Recurrent STXBP1 variants found in five or more individuals. (B) The STXBP1 protein (top) and gene (bottom), highlighting a selection of recurrent variant hotspots. The proportion of STXBP1 disorder-associated versus population variants is shown below, highlighting (grey) regions in which the difference is significant. (C) Distribution of variant types. Splice site, frameshift variants and whole and partial gene deletions were included in the PTV/del group.CC BY · PubMed Central
Figure 2 Individuals reported with STXBP1-related disorders and associated phenotypic features across subgroups. (A) Distribution of phenotypic features in the overall cohort of 534 individuals. Radial lines indicate frequency of terms in the respective cohort. 1: seizures; 2: abnormality of higher mental function; 3: delayed speech and language development; 4: global developmental delay; 5: Intellectual disability; 6: Neurodevelopmental abnormality; 7: Neurological speech impairment; 8: Abnormal muscle tone; 9: Abnormality of coordination; 10: Abnormality of movement; 11: gait disturbance; 12: involuntary movements; 13: muscular hypotonia; 14: stereotypy; 15: behavioural abnormality; 16: bruxism; 17: infantile onset; 18: neonatal onset; 19: paediatric onset; 20: sleep disturbance; 21: EEG with burst suppression; 22: EEG with focal epileptiform discharges; 23: EEG with generalized epileptiform discharges; 24: epileptic spasms; 25: focal-onset seizure; 26: generalized-onset seizure; 27: generalized tonic–clonic seizures; 28: hypsarrhythmia; 29: infantile spasms; 30: interictal epileptiform activity; and 31: multifocal epileptiform discharges. (B) Individuals were grouped into broad phenotypic groups: EOEE (n = 163), neurodevelopmental disorders (NDD, n = 129), developmental and epileptic encephalopathy not otherwise specified (other DEE, n = 103), West syndrome (n = 77), Ohtahara syndrome (n = 49) and atypical Rett syndrome (n = 13). (C) Distribution of phenotypic features across subgroups.
Figure 2 Individuals reported with STXBP1-related disorders and associated phenotypic features across subgroups. (A) Distribution of phenotypic features in the overall cohort of 534 individuals. Radial lines indicate frequency of terms in the respective cohort. 1: seizures; 2: abnormality of higher mental function; 3: delayed speech and language development; 4: global developmental delay; 5: Intellectual disability; 6: Neurodevelopmental abnormality; 7: Neurological speech impairment; 8: Abnormal muscle tone; 9: Abnormality of coordination; 10: Abnormality of movement; 11: gait disturbance; 12: involuntary movements; 13: muscular hypotonia; 14: stereotypy; 15: behavioural abnormality; 16: bruxism; 17: infantile onset; 18: neonatal onset; 19: paediatric onset; 20: sleep disturbance; 21: EEG with burst suppression; 22: EEG with focal epileptiform discharges; 23: EEG with generalized epileptiform discharges; 24: epileptic spasms; 25: focal-onset seizure; 26: generalized-onset seizure; 27: generalized tonic–clonic seizures; 28: hypsarrhythmia; 29: infantile spasms; 30: interictal epileptiform activity; and 31: multifocal epileptiform discharges. (B) Individuals were grouped into broad phenotypic groups: EOEE (n = 163), neurodevelopmental disorders (NDD, n = 129), developmental and epileptic encephalopathy not otherwise specified (other DEE, n = 103), West syndrome (n = 77), Ohtahara syndrome (n = 49) and atypical Rett syndrome (n = 13). (C) Distribution of phenotypic features across subgroups.CC BY · PubMed Central
Figure 3 Seizure patterns in a subset of individuals with STXBP1-related disorders. (A) Cumulative distribution of seizure onset in 427 individuals and seizure offset in 80 individuals, highlighting 89% of individuals with seizure onset in the first year of life and offset within the first 5 years. Seizure onset interquartile range (IQR): 0.24–5.0 months. Seizure offset IQR: 5.75 months–1.6 years. (B) Changes in seizure frequency in monthly intervals during the first year of life, indicating a dynamic course of seizures in individuals with STXBP1. Progression in blue between monthly increments indicates seizure improvement, whereas yellow indicates seizures worsening and grey indicates no change in seizure frequency.
Figure 3 Seizure patterns in a subset of individuals with STXBP1-related disorders. (A) Cumulative distribution of seizure onset in 427 individuals and seizure offset in 80 individuals, highlighting 89% of individuals with seizure onset in the first year of life and offset within the first 5 years. Seizure onset interquartile range (IQR): 0.24–5.0 months. Seizure offset IQR: 5.75 months–1.6 years. (B) Changes in seizure frequency in monthly intervals during the first year of life, indicating a dynamic course of seizures in individuals with STXBP1. Progression in blue between monthly increments indicates seizure improvement, whereas yellow indicates seizures worsening and grey indicates no change in seizure frequency.CC BY · PubMed Central
Figure 4 Phenograms of missense variants versus PTV and most frequent recurrent variant hotspots. (A) Phenogram comparing the frequency of phenotypic features in individuals with PTV/del (n = 261) and individuals with missense variants (n = 255). PTV/dels included splice sites, frameshifts and whole and partial gene deletions. (B) Phenogram comparing the frequency of phenotypic features in individuals with variants in p.Arg406Cys/His and the remainder of the cohort. (C) Phenogram comparing the frequency of phenotypic features in individuals with variants in p.Arg292Cys/His/Leu/Pro and the remainder of the cohort. (D) Phenogram comparing the frequency of phenotypic features in individuals with variants in p.Arg551Cys/Gly/His/Leu and the remainder of the cohort. Red points indicate HPO terms with uncorrected P-values < 0.05, while blue points indicate HPO terms with uncorrected P-values ≥ 0.05. Size of points indicate −log10(P-value).
Figure 4 Phenograms of missense variants versus PTV and most frequent recurrent variant hotspots. (A) Phenogram comparing the frequency of phenotypic features in individuals with PTV/del (n = 261) and individuals with missense variants (n = 255). PTV/dels included splice sites, frameshifts and whole and partial gene deletions. (B) Phenogram comparing the frequency of phenotypic features in individuals with variants in p.Arg406Cys/His and the remainder of the cohort. (C) Phenogram comparing the frequency of phenotypic features in individuals with variants in p.Arg292Cys/His/Leu/Pro and the remainder of the cohort. (D) Phenogram comparing the frequency of phenotypic features in individuals with variants in p.Arg551Cys/Gly/His/Leu and the remainder of the cohort. Red points indicate HPO terms with uncorrected P-values < 0.05, while blue points indicate HPO terms with uncorrected P-values ≥ 0.05. Size of points indicate −log10(P-value).CC BY · PubMed Central
Figure 5 Reconstruction of seizure frequency in monthly increments. (A) Changes in seizure severity with time in one individual with STXBP1-related disorder are shown. Seizure severity is represented by ordinal seizure frequency (SF) scores: multiple daily seizures (SF = 5), several daily seizures (SF = 4), daily seizures (SF = 3), weekly seizures (SF = 2), monthly seizures (SF = 1), no seizures (SF = 0). (B) Pattern of seizure frequency in individuals with seizures, regardless of type (HP:0001250, n = 43). Seizure frequencies of individuals tracked across time (left), each row along the y-axis representing a unique individual. Colour and size of dots represent seizure severity. Median severity in the subgroup with size of dots indicating number of individuals (right). (C) Pattern of seizure frequency in individuals with infantile spasms (HP:0012469, n = 19). (D) Pattern of seizure frequency in individuals with focal impaired awareness seizures (HP:0002384, n = 16).
Figure 5 Reconstruction of seizure frequency in monthly increments. (A) Changes in seizure severity with time in one individual with STXBP1-related disorder are shown. Seizure severity is represented by ordinal seizure frequency (SF) scores: multiple daily seizures (SF = 5), several daily seizures (SF = 4), daily seizures (SF = 3), weekly seizures (SF = 2), monthly seizures (SF = 1), no seizures (SF = 0). (B) Pattern of seizure frequency in individuals with seizures, regardless of type (HP:0001250, n = 43). Seizure frequencies of individuals tracked across time (left), each row along the y-axis representing a unique individual. Colour and size of dots represent seizure severity. Median severity in the subgroup with size of dots indicating number of individuals (right). (C) Pattern of seizure frequency in individuals with infantile spasms (HP:0012469, n = 19). (D) Pattern of seizure frequency in individuals with focal impaired awareness seizures (HP:0002384, n = 16).CC BY · PubMed Central
Figure 6 Comparative effectiveness assessment of ASM and treatment responses. (A) Selection of ASM prescriptions extracted from the EMR, across ages 0–5 years in a subset of individuals with STXBP1. (B) Extension of A, showing the distribution of individuals on ASM and ketogenic diet across ages 0–20 years. (C) Relative effectiveness of ASM in reducing seizure frequency. (D) Relative effectiveness of ASM in reducing seizure frequency or maintaining seizure freedom. (E) Relative effectiveness of ASM in maintaining seizure freedom. Odds ratios were calculated based on changes in seizure frequency to ASM use across monthly time intervals.
Figure 6 Comparative effectiveness assessment of ASM and treatment responses. (A) Selection of ASM prescriptions extracted from the EMR, across ages 0–5 years in a subset of individuals with STXBP1. (B) Extension of A, showing the distribution of individuals on ASM and ketogenic diet across ages 0–20 years. (C) Relative effectiveness of ASM in reducing seizure frequency. (D) Relative effectiveness of ASM in reducing seizure frequency or maintaining seizure freedom. (E) Relative effectiveness of ASM in maintaining seizure freedom. Odds ratios were calculated based on changes in seizure frequency to ASM use across monthly time intervals.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 130

Metadata

Authors
Xian, J., Parthasarathy, S., Ruggiero, S. M., Balagura, G., Fitch, E., Helbig, K., Gan, J., Ganesan, S., Kaufman, M. C., Ellis, C. A., Lewis-Smith, D., Galer, P., Cunningham, K., O’Brien, M., Cosico, M., Baker, K., Darling, A., Veiga de Goes, F., El Achkar, C. M., Doering, J. H., Furia, F., García-Cazorla, Á., Gardella, E., Geertjens, L., Klein, C., Kolesnik-Taylor, A., Lammertse, H., Lee, J., Mackie, A., Misra-Isrie, M., Olson, H., Sexton, E., Sheidley, B., Smith, L., Sotero, L., Stamberger, H., Syrbe, S., Thalwitzer, K. M., van Berkel, A., van Haelst, M., Yuskaitis, C., Weckhuysen, S., Prosser, B., Son Rigby, C., Demarest, S., Pierce, S., Zhang, Y., Møller, R. S., Bruining, H., Poduri, A., Zara, F., Verhage, M., Striano, P., & Helbig, I.
Affiliations
  • Children's Hospital of Philadelphia (US)
  • Istituto Giannina Gaslini (IT)
  • Sichuan University (CN)
  • Translational and Clinical Research Institute, Newcastle University , Newcastle-upon-Tyne NE2 4HH, UK
  • MRC Cognition and Brain Sciences Unit (GB)
  • Hospital Sant Joan de Déu Barcelona (ES)
  • Department of Pediatrics and Pediatric Neurology Laboratory, Instituto Fernandes Figueira , Rio de Janeiro 22250-020, Brazil
  • Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital , Boston, MA, USA
  • University Hospital Heidelberg (DE)
  • Filadelfia (DK)
  • Pediatric Neurology Department, Hospital Sant Joan de Déu, University of Barcelona , Barcelona, Spain
  • Amsterdam University Medical Centers (NL)
  • Children's Hospital Colorado (US)
  • MRC Cognition and Brain Sciences Unit, University of Cambridge , Cambridge, UK
  • Samsung Medical Center (KR)
  • Department of Human Genetics, Center for Neurogenomics and Cognitive Research (CNCR), Amsterdam University Medical Center , de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
  • Boston Children's Hospital (US)
  • Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (BR)
  • Antwerp University Hospital (BE)
  • Department of Functional Genomics, Center for Neurogenomics and Cognitive Research (CNCR), VU University Amsterdam , De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
  • University of Antwerp (BE)
  • Department of Physiology, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA 19104, USA
  • STXBP1 Foundation , Apex, NC 27539, USA
  • Peking University (CN)
Corresponding author
Helbig, Ingo
Venue
Brain
Published
2021-11-23
Volume
145
Issue
5
Pages
1668-1683
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4206071515
Cited by
130
References
40
Citations by year
2026: 28 · 2025: 30 · 2024: 39 · 2023: 18 · 2022: 15
FWCI
12.92
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • VU Research Portal (publishedVersion, other-oa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Children's Hospital of Philadelphia (UL1TR001878, HD086984, U54 HD086984)
  • Hartwell Foundation
  • University of Pennsylvania (UL1 TR001878, U54HD086984)
  • Institute for Translational Medicine and Therapeutics (UL1TR001878)
  • Wellcome Trust (203914/Z/16/Z)
  • European Science Foundation (HE5415/3‐1, HE5415/5-1, HE5415/6-1)
  • Great Ormond Street Hospital Charity
  • Deutsche Forschungsgemeinschaft (We4896/4-570 1, FOR‐2715, 2018-2022, HE 5415/6-1, HE5415/5‐1, HE5415/7-1, WE4896/3-1, HE5415/3-1, We4896/4-570, INTER/DFG/17/11583046)
  • Fonds Wetenschappelijk Onderzoek
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024.004.012, NWO 024.004.012)
  • Ministero dell’Istruzione, dell’Università e della Ricerca (20182022, legge 232 del 2016, MIUR 2018-2022)
  • National Institutes of Health (2018-2022, HD086984, UL1TR001878)
  • Intellectual and Developmental Disabilities Research Center (U54 HD086984)
  • Perelman School of Medicine, University of Pennsylvania (MDBR-20-136-STXBP1, UL1TR001878)
  • Medical Research Council (MC_UU_00030/3, G101400)
  • National Institute of Neurological Disorders and Stroke (K23NS107646, K02NS112600, T32NS091008, U24NS120854, K23NS121520)
  • National Institute of Child Health and Human Development
  • National Center for Advancing Translational Sciences
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD086984, P50HD105351)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
STXBP1, neurodevelopmental disorders, phenotypic spectrum, seizures, infantile spasms, West syndrome, focal seizures, truncating mutations, recurrent variants, seizure history, seizure control, antiepileptic drugs, ketogenic diet, phenobarbital, ACTH, seizure onset
MeSH terms
Electroencephalography, Epilepsy, Humans, Infant, Retrospective Studies, Seizures, Spasms, Infantile, Munc18 Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.